Notice Regarding the Conclusion of Joint Sales Promotion Contract Concerning Alesion® Ophthalmic Solution 0.05% and Alesion® LX Ophthalmic Solution 0.1% between Mitsubishi Tanabe Pharma and Santen Pharmaceutical Co., Ltd.

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka City; President & Representative Director, CEO: Masayuki Mitsuka; hereinafter, “Mitsubishi Tanabe Pharma”) announced today that the Company concluded a joint sales promotion contract concerning Alesion® Ophthalmic Solution 0.05% (generic name: Epinastine Hydrochloride; hereinafter, “Alesion”), which is an anti-allergenic ophthalmic solution currently manufactured and marketed by Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; Chairman and CEO: Akira Kurokawa; hereinafter, “Santen”), and Alesion® LX Ophthalmic Solution 0.1% (generic name: Epinastine Hydrochloride; hereinafter, “Alesion LX”), for which Santen has obtained approval in Japan today.

Based on this contract, Santen will manufacture and distribute these products, while both companies will conduct promotional activities to medical institutions starting October 1, 2019. Mitsubishi Tanabe Pharma will be in charge of medical institutions other than ophthalmology, and Santen will be in charge of medical institutions of ophthalmology.

Alesion LX is an ophthalmic solution based on an in-license from Nippon Boehringer Ingelheim Co., Ltd. and was developed in Japan by Santen as a treatment for allergic conjunctivitis. Alesion LX is a high-dose formulation of Alesion, which has been marketed in Japan since 2013. Epinastine hydrochloride, the active ingredient of Alesion LX, is histamine H₁ receptor antagonist and suppresses the release of chemical mediators from mast cells. Clinical trials conducted in Japan have demonstrated that the active ingredient of Alesion LX can reach the eye tissues in higher amount and work there for a longer time so that eye itching and conjunctival redness as the main symptoms of allergic conjunctivitis can be suppressed by applying twice a day. In addition, no serious side effects have been observed in either the eyes or the entire body.
In November 2017, Mitsubishi Tanabe Pharma began to distribute the allergy treatment agent Rupafin® Tablets 10mg. Moving forward, the Company will strive to make a wide range of treatment proposals for allergies by adding ophthalmic solution to internal medicine. In this way, the Company will help to increase the quality of life (QOL) and treatment of patients.

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department
Media contacts: TEL:+81 6 6205 5119
Investor contacts: TEL:+81 6 6205 5110